We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

MaxCyte

Reaping continued returns from R&D

Update | 19 September 2017

e-therapeutics

Refining its focus

Update | 24 July 2017

Sphere Medical

Funding to support Proxima 4 roll-out being finalised

Update | 14 July 2017

MaxCyte

Consolidating its leadership

Update | 13 July 2017

e-therapeutics

Rebooted drug discovery

Initiation | 27 June 2017

MaxCyte

From strength to strength, with CARMA expansion

Outlook | 07 June 2017

Sphere Medical

Commercialisation is underway

Update | 02 May 2017

Serodus

Setting the scene for a significant shift

Outlook | 22 March 2017

MaxCyte

A year to remember

Update | 20 March 2017

MaxCyte

Maiden commercial deal announced for use in CRISPR

Update | 14 March 2017
1 2 3 4 5 6 7 8 9 10 11
105 results found.